Excited to share our publication with @Tom_Nolin ( and the @RustbeltCFAR about quantifying plasma concentrations of lenacapavir! Plenty of fun #lenacapavir clin PK studies to occur at @pittpharmacy! @GileadSciences @GileadHIV

RT @ACCP: The Department of Pharmacy & Therapeutics of the University of Pittsburgh School of Pharmacy is accepting applications for a full…

RT @pittpharmacy: Continuing our Spotlight Series, congrats to Dr. Aaron Devanathan, who was selected to attend the Society of Research Adm…

RT @ACCP: The University of Pittsburgh School of Pharmacy Department of Pharmacy & Therapeutics is accepting applications for a full-time t…

It's an exciting time! And even more excited to share that I'm recruiting for a clinical pharmacology fellowship in the HIV/AIDS therapeutic area! Check out the link below and feel free to reach out to me if you have any questions. Feel free to share!

Rome wasn't built in a day...and neither was the #AntiviralPK workshop! Congratulations to Mattia Berton for Best Abstract Award! What a great meeting and can't wait until next year in...Liverpool!!! Thank you all and to @Academic_MedEdu @AlicePharmd @KimScarsi

Does tissue pharmacology matter? Dr. Saye Khoo at #AntiviralPK provided a comprehensive analysis of PK/PD in the tissues. This is a large and complex topic so huge kudos for the overview. Many more questions remain, especially as we enter a new era in ART!

The issues are the tissues! Dr. Charles Flexner at the #AntiviralPK workshop discussed the knowledge gaps related to tissue-specific pharmacology. By using LSD and sildenafil as pharmacological examples, we have learned the tissue-specific PK/PD may not be reflected in plasma.

Examining RMD for HIV-1 latency and its PK endpoints? We learned in an abstract presentation at #AntiviralPK from @CPACLab through a comprehensive dose fractionation study that time correlates with HIV transcription. In the hollow fiber model, Time>EC90 correlated as well.

NMV/r with MPV for COVID in saliva, tear, and nasal was discussed at #AntiviralPK. The AGILE CST-8 study noted NMV penetrates into tears and nasal compartments and aligned well with previous studies. 100% of tear and nasal concentrations were above PK thresholds. BOLO for more!

PrEP in TGW in blood and rectum was the subject of an abstract presentation at #AntiviralPK from @CPACLab. FHT may alter PrEP PK and in this study, FHT hadn't decreased pooled TFV or FTC in either blood or rectum and estradiol wasn't correlated with PrEP concentrations.

Blood sampling devices are not created equal, as discussed during an abstract presentation at #AntiviralPK from @CPACLab. Although inconsistent sponge filling was observed among devices, there had been good agreement with DBS and devices. Device testing before studies is key.

Concluding our industry session at #AntiviralPK is Dr. Xiao-Jian Zhou at @ateapharma discussing bemnifosbuvir for HCV! Bemnifosbuvir has dual activity against HCV (in combo with ruzasvir) and COVID, and these studies are ongoing. BOLO for more info on these antivirals!

Continuing the industry session at #AntiviralPK is Dr. Simon Portsmouth at @SHIONOGI_JP to discuss the development of antivirals for influenza and SARS-Cov-2! We learned about the clinical and virologic outcomes and the PK properties of these newer antivirals.

Next up in the industry session at #AntiviralPK is Dr. Jon Collins from @ViiVHC @ViiVUS to provide insight into the drug pipeline! Long-acting and ultra-LA, new classes of ARVs, new formulations of current ARVs, antibody therapies, complex PK properties, oh my!

Welcome to Day 3 of the #AntiviralPK workshop! Starting us off is Dr. Ramesh Palaparthy from @GileadSciences to discuss long-acting therapies! We learned the lore and development of lenacapavir, its properties suitable for long-acting formulations, and its PK profiles.

NMV/r and anticoagulants...what's the deal? At #AntiviralPK, an abstract presentation discussed the safety and management of these DDIs in ambulatory settings. 11 patients had changes to anticoag tx, either a dose decrease or an alternative agent with no reports of TE events.

NMV/r DDIs with anticancer drugs are understudied and at #AntiviralPK, real-world management of NMV/r with systemic cancer tx was discussed in an abstract presentation. There were 40 instances of clinically significant DDIs and increased potential for toxicity of cancer tx.

Continuing the NMV/r discussion at #AntiviralPK, an abstract presentation discussed the real-world DDI management with co-medications. 184 total DDIs were flagged, and more will be reported with greater adoption. Having these systems is important for clinical decision-making.

Teamwork makes the dream work! Dr. Alice Pau from the @NIH at #AntiviralPK discussed the history and lore of the Cross-Atlantic Collaboration to standardize DDI management with nirmatrelvir/r. Given more widespread use and comorbidities, this was an urgent matter.